The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 MPN patients and 43,550 matched controls with the aim to assess the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of MPN. We found a prior history of any autoimmune disease to be associated with a significantly increased risk of MPNs (odds ratio (OR)=1.2; 95% confidence interval (CI) 1.0-1.3; p= 0.021). Specifically, we found an increased risk of MPNs associated with a prior immune thrombocytopenic purpura (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7) . The risk of MPNs associated with prior autoimmune diseases is modest but statistically significant. Future studies are needed to unravel the effects of these autoimmune diseases themselves, their treatment, or common genetic susceptibility.
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INTRODUCTION
Chronic myeloproliferative disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are termed myeloproliferative neoplasms (MPNs). 1 Biologically, they are thought to be stem cell-derived clonal proliferative myeloid malignancies whose shared and diverse phenotypic characteristics can be attributed to dysregulated signal transduction because of acquired somatic mutations.
2
MPNs are uncommon tumors with yearly incidence rates of 2.3 in 100,000 in the United States 3 . MPNs primarily affect older adults and can have a variable clinical presentation. [4] [5] [6] [7] The underlying causes of MPNs are largely unknown. A mutation in the gene for Janus kinase 2, (JAK2)V617F, is present in most erythropoietin-independent erythroid colonies in PV. 8 The mutation is present in 95% of PV patients and in approximately 50% of ET and PMF patients. 2 However, other primary pathogenetic mutations have been hypothesized. 9 A role for hereditary factors in the etiology of MPNs has been suggested. We recently performed a large population-based study including more than 11,000 MPN patients and found 5-7 fold risk of developing MPNs among first-degree relatives of MPN patients, compared to first-degree relatives of controls. 4 Furthermore, recent studies suggest that the JAK2 gene is a susceptibility gene for MPNs both in the germline and somatically. [10] [11] [12] A personal history of autoimmune diseases has been consistently associated with an increased risk of lymphomas. 13, 14 Interestingly, there are emerging data to suggest that autoimmunity could play a role in the development of myeloid malignancies such as acute and chronic myeloid leukemias. 15 However, due to the rarity of MPNs, there are only sparse data available regarding the association between autoimmune diseases and risk of developing MPNs. 15, 16 To improve our understanding on this topic, we conducted a large population-based study including more than 11,000 MPN patients and more than 43,000 matched controls. The aim of our study was to assess the associations between a personal history of a broad span of autoimmune diseases and subsequent risk of MPN.
DESIGN AND METHODS
The details of the study population have been described previously. 4 We identified all incident patients diagnosed from 1958 to 2005 with a MPN from the nationwide Swedish Cancer
Registry. In addition, we retrieved information on incident MPN patients through our national MPN network.
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For each MPN patient, four population-based controls matched by sex, year of birth, and county were chosen randomly from the Swedish Population database. All controls had to be alive at the time of MPN diagnosis for the corresponding case and free of hematological malignancy at the date of the corresponding case's diagnosis.
Information on occurrence and date of autoimmune disease was obtained from the Inpatient
Registry.
Using logistic regression models adjusted for age, sex, calendar period, and region, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) as measures of relative risks.
To limit the influence of detection bias, we excluded autoimmune disease diagnosed less than one year prior to MPN diagnosis.
RESULTS AND DISCUSSION
A total of 11,039 (6217 PV, 2838 ET, 1172 PMF, and 812 MPN not otherwise specified (NOS)) MPN patients diagnosed in Sweden in 1958-2005 together with 43,550 populationbased matched controls were included in our study (Table 1) .
A total of 288 (2.6%) MPN patients had a previous personal history of autoimmunity. A prior history of any autoimmune disease was associated with an increased risk of MPNs (OR=1.2; 95% CI 1.0-1.3; p= 0.021; Table 2 ). Furthermore, there was an increased risk associated with autoimmune diseases without detectable antibodies (1.6; 1.3-2.0; Table 2 ). Specifically, we
found an increased risk of MPNs associated with a prior history of immune thrombocytopenic purpura (ITP) (2.9; 1.7-7.2), Crohn's disease (1.8; 1.1-3.0), polymyalgia rheumatica (PMR) (1.7; 1.2-2.5), giant cell arteritis (5.9; 2.4-14.4), Reiter's syndrome (15.9; 1.8-142) and aplastic anemia (7.8; 3.7-16.7). In analyses stratified by MPN subgroup, age at diagnosis, and sex, based on small numbers, the results were virtually unchanged ( Table 2 ).
In the most comprehensive investigation to date, we assessed a broad range of autoimmune diseases in relation to specific MPNs. We found that individuals with a prior history of any autoimmune disease had a 20% increased risk of developing an MPN. When we evaluated individual autoimmune diseases, we found a 2-to 3-fold elevated risk for MPNs among patients with a history of ITP, Crohn's disease, and PMR. The most prominent risks were found among persons with a history of giant cell arteritis, aplastic anemia, and Reiter's syndrome. Our findings are consistent with the only prior, to our knowledge, study based on 18 Interestingly, a recent genome-wide association study in patients with Crohn's disease found evidence of an association in the region containing JAK2. 19 We found prior history of PMR and giant cell arteritis to be associated with an increased risk of MPNs. It has been suggested that the prevalence of cancer is increased in patients with giant cell arteritis, however this is controversial. 20, 21 PMR and giant cell arteritis can mimick other conditions, with features such as thrombocytosis and leukocytosis, with patients being misclassified as MPNs. 22, 23 However, in our latency analyses on PMR we found the risk estimate to be significantly elevated more than five years prior to MPNs.
Further, aplastic anemia, characterized by pancytopenia and reduced marrow cellularity is treated with immunosuppressive therapy and/or stem cell transplantation. It is associated with an increased risk for myelodysplastic syndrome, leukemias and some solid tumors. [24] [25] [26] It has not been previously associated with risk of MPNs.
Strengths of our study include its large size and high-quality data from Sweden in a stable population with access to standardized universal medical health care during the study period.
Furthermore, the use of the nationwide register-based case-control design ruled out recall-bias and ensured a population-based setting and generalizability of our findings.
Limitations include lack of clinical data, lack of information on potential confounders (although the design ensured adjustment for sex, age, and geography), absence of a systematic blinded validation of all MPN diagnoses, and a large number of tested variables. Furthermore, the use of inpatient data led to under-ascertainment of less severe forms of autoimmune diseases and our findings may apply mainly to severe forms of autoimmunity. However, because personal history of autoimmune diseases was assessed similarly among the patients
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with MPN and controls, any under-diagnosis should be non-differential, and any bias should be toward the null.
In conclusion, the research field in MPN is rapidly evolving, and progress is being made in understanding the pathogenesis of these diseases. Based on over 11,000 MPN patients, we found individuals with a personal history of autoimmunity to have a 20% increased risk of developing an MPN. Certain autoimmune conditions, including giant cell arteritis, aplastic anemia, and Reiter's syndrome were associated with highly elevated risks. Future studies are needed to uncover underlying mechanisms of our novel findings. 
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